Inato, a Paris, France-based platform for biopharmaceutical companies to increase the pool of available patients engaged in clinical trials, raised $14m in Series A funding.
The round was led by Obvious Ventures and Cathay Innovation, with participation from previous investors Serena and Fly Ventures.
As a part of the financing, Nan Li, managing director at Obvious Ventures, has joined Inatoâ€™s board of directors.
The company intends to use the funds to expand its predictive capabilities to match the right sites with the right studies and develop a comprehensive network of clinicians worldwide.
To date, the company has helped biopharmaceutical companies and clinicians across more than 2,000 research sites and over 50 global trials.
Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.
Advertise with us to boost your article, content pience, product, event, conference discovery to our readers which includes founders, startup enablers, investors and every key stakeholders from global startup eco-system.